Trial Profile
An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Sep 2022
Price :
$35
*
At a glance
- Drugs Centanafadine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 01 Apr 2022 Status changed from active, no longer recruiting to completed.
- 24 Aug 2020 Status changed from recruiting to active, no longer recruiting.
- 15 Jul 2020 Planned End Date changed from 1 Jun 2021 to 1 Sep 2021.